These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24965981)

  • 1. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset.
    Akkermans J; Payne B; von Dadelszen P; Groen H; Vries Jd; Magee LA; Mol BW; Ganzevoort W
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():58-62. PubMed ID: 24965981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model.
    von Dadelszen P; Payne B; Li J; Ansermino JM; Broughton Pipkin F; Côté AM; Douglas MJ; Gruslin A; Hutcheon JA; Joseph KS; Kyle PM; Lee T; Loughna P; Menzies JM; Merialdi M; Millman AL; Moore MP; Moutquin JM; Ouellet AB; Smith GN; Walker JJ; Walley KR; Walters BN; Widmer M; Lee SK; Russell JA; Magee LA;
    Lancet; 2011 Jan; 377(9761):219-27. PubMed ID: 21185591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission.
    Payne B; Hodgson S; Hutcheon JA; Joseph KS; Li J; Lee T; Magee LA; Qu Z; von Dadelszen P;
    BJOG; 2013 Jan; 120(1):113-8. PubMed ID: 23078362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia.
    Ukah UV; Payne B; Karjalainen H; Kortelainen E; Seed PT; Conti-Ramsden FI; Cao V; Laivuori H; Hutcheon J; Chappell L; Mark Ansermino J; Vatish M; Redman C; Lee T; Li L; Magee LA; von Dadelszen P;
    Pregnancy Hypertens; 2019 Jan; 15():42-50. PubMed ID: 30825926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of complications of pre-eclampsia using the fullPIERS high risk predictive model.
    Sharma A; Suri J; Khanam Z; Pandey D; Bachani S; Sharma A
    Int J Gynaecol Obstet; 2023 Dec; 163(3):983-988. PubMed ID: 37328916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of fullPIERS model for prediction of adverse outcomes among women with severe pre-eclampsia.
    Almeida ST; Katz L; Coutinho I; Amorim MMR
    Int J Gynaecol Obstet; 2017 Aug; 138(2):142-147. PubMed ID: 28475234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the fullPIERS model for prediction of adverse outcomes in preeclampsia at a referral center.
    Guida JP; Cralcev C; Costa Santos J; Marangoni-Junior M; Sanchez MP; Laura Costa M
    Pregnancy Hypertens; 2021 Mar; 23():112-115. PubMed ID: 33310390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placental growth factor for the prognosis of women with preeclampsia (fullPIERS model extension): context matters.
    Ukah UV; Payne BA; Hutcheon JA; Chappell LC; Seed PT; Conti-Ramsden FI; Ansermino JM; Magee LA; von Dadelszen P;
    BMC Pregnancy Childbirth; 2020 Nov; 20(1):668. PubMed ID: 33153436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [External validation of FullPIERS model for prediction of adverse outcomes among women with pre-eclampsia in French maternity of 2014 to 2018].
    Boutot M; Margueritte F; Boukeffa N; Coste Mazeau P; Aubard Y; Gauthier T
    Gynecol Obstet Fertil Senol; 2020 Feb; 48(2):167-173. PubMed ID: 31923643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries.
    Ukah UV; Payne B; Lee T; Magee LA; von Dadelszen P;
    Hypertension; 2017 Apr; 69(4):705-711. PubMed ID: 28167685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of Prediction models for Risks of complications in Early-onset Pre-eclampsia (PREP): a prospective cohort study.
    Thangaratinam S; Allotey J; Marlin N; Mol BW; Von Dadelszen P; Ganzevoort W; Akkermans J; Ahmed A; Daniels J; Deeks J; Ismail K; Barnard AM; Dodds J; Kerry S; Moons C; Riley RD; Khan KS
    Health Technol Assess; 2017 Apr; 21(18):1-100. PubMed ID: 28412995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia.
    Ukah UV; Payne B; Hutcheon JA; Ansermino JM; Ganzevoort W; Thangaratinam S; Magee LA; von Dadelszen P
    Hypertension; 2018 Apr; 71(4):659-665. PubMed ID: 29440330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics and incidence patterns of maternal complications in early-onset hypertension of pregnancy.
    Ganzevoort W; Rep A; Bonsel GJ; De Vries JI; Wolf H;
    BJOG; 2007 Jun; 114(6):741-50. PubMed ID: 17516967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria in pre-eclampsia: how much matters?
    Chan P; Brown M; Simpson JM; Davis G
    BJOG; 2005 Mar; 112(3):280-5. PubMed ID: 15713140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy.
    Ganzevoort W; Rep A; de Vries JI; Bonsel GJ; Wolf H;
    Am J Obstet Gynecol; 2006 Aug; 195(2):495-503. PubMed ID: 16643825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study.
    Payne BA; Hutcheon JA; Ansermino JM; Hall DR; Bhutta ZA; Bhutta SZ; Biryabarema C; Grobman WA; Groen H; Haniff F; Li J; Magee LA; Merialdi M; Nakimuli A; Qu Z; Sikandar R; Sass N; Sawchuck D; Steyn DW; Widmer M; Zhou J; von Dadelszen P;
    PLoS Med; 2014 Jan; 11(1):e1001589. PubMed ID: 24465185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis.
    Koopmans CM; van Pampus MG; Groen H; Aarnoudse JG; van den Berg PP; Mol BW
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):8-14. PubMed ID: 19540647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center.
    Yücesoy G; Ozkan S; Bodur H; Tan T; Calişkan E; Vural B; Corakçi A
    Arch Gynecol Obstet; 2005 Nov; 273(1):43-9. PubMed ID: 15834580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preeclampsia and fetal growth.
    Odegård RA; Vatten LJ; Nilsen ST; Salvesen KA; Austgulen R
    Obstet Gynecol; 2000 Dec; 96(6):950-5. PubMed ID: 11084184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-analysis.
    Thangaratinam S; Gallos ID; Meah N; Usman S; Ismail KM; Khan KS;
    Acta Obstet Gynecol Scand; 2011 Jun; 90(6):564-73. PubMed ID: 21355860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.